Clinical Trial Update: Activity Study of Sunitinib In Metastatic Pretreated Urothelial Cancer [Phase 1, Phase 2]

View source ↗

Summary

This document reports a Phase 1/2 activity study of sunitinib in metastatic, previously treated urothelial cancer (bladder cancer).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: Campania Younger Oncologists Association | Conditions: Urinary Bladder Neoplasms | Phase 1, Phase 2 | Status: UNKNOWN